PURPOSE:
For molecular genetic diagnosis of prognosis markers of the course of the disease with viral hepatitis C; evaluating the effectiveness and side effects of treatment according to the standard scheme (pegylated interferon and ribavirin) for the appointment of an individual therapy regimen, based on the results of DNA diagnostics of the patient’s pharmacogenetic markers.
DESCRIPTION:
A laboratory sample containing a diagnostic kit of reagents and a technological scheme for DNA analysis of allelic variants of the TLR3, IFNL4, and ITRA genes – markers for predicting the course of viral hepatitis C and individual response to treatment according to the standard scheme. Development readiness level IRL5, TRL5. On request, we carry out the production of test samples, as well as the training of personnel.
ADVANTAGES:
There are no analogues. The use of the test system will allow to determine the features of the genetic profile and prescribe a personalized scheme of effective treatment.
RECOMMENDED FIELD OF APPLICATION:
Medicine. Specialized diagnostic laboratories, health care institutions of Ukraine.
RESULTS OF THE RESEARCH:
Provides consistent results.
STAGE OF THE DEVELOPMENT READINESS:
Ready for implementation.
TRANSFER OPPORTUNITY:
-
- Realization of finished products.
- Co-production, sale, operation.
NOVELTY:
2 foreign patents.
IF YOU ARE INTERESTED IN THIS DEVELOPMENT, PLEASE,
WRITE TO US